Therefore , we investigated the relative bioavailability of RFP from one four-drug fixed-dose combination ( FDC ; formulation A ) and three two-drug FDCs ( formulations B , C , and D ) used in China , compared with RFP in free combinations of these drugs ( reference ) , in healthy volunteers .